Phase 2 Study to Assess the Safety and Efficacy of ANG003

Conditions

• Exocrine Pancreatic Insufficiency (EPI)
• Cystic Fibrosis (CF)

Interventions

• DRUG: ANG003 Dose A
• DRUG: ANG003 Dose B
• DRUG: Creon

Sponsor

Anagram Therapeutics, Inc.